Leading the Way in Regulatory T Cell (Treg) Suppression Assays – Precision, Expertise, Results

In the realm of immunological research and drug development, accurately assessing Treg function is crucial. Creative Biolabs provides comprehensive and meticulously designed in vitro Treg suppression assay services, ensuring high-quality and reliable results for your immunological research and drug development needs.

Our in vitro Treg suppression assay services:

• Treg Isolation and Purification
  
  • Sample Collection and Preparation: We start with peripheral blood mononuclear cells (PBMCs) or tissue samples, preparing them under sterile conditions to maintain cell viability.
  • Isolate Treg Cells by Cell Sorting: We selectively isolate Treg cells based on the expression of CD4, CD25, and FoxP3 markers, achieving a high purity of over 95%.
  • Fluorescence-Activated Cell Sorting (FACS): For even higher purity, we employ FACS, sorting cells based on fluorescently labeled antibodies targeting Treg-specific surface markers.
• Coculture Experiment Design
  
  • Optimization of Cell Ratios: We determine the optimal Treg to effector T cell (Teff) ratio through preliminary experiments to maximize the reliability of suppression measurements.
  • Teff Cell Activation: Effector T cells are activated using agents such as anti-CD3/CD28 antibodies or specific antigens, ensuring robust proliferation and function that Tregs can modulate.
  • Coculture Conditions: We set up coculture conditions that mimic physiological environments, including appropriate media, supplements, and incubation parameters to support cell viability and interaction.
• Suppression Function Evaluation
  
  • Proliferation Inhibition Assay: Using carboxyfluorescein succinimidyl ester (CFSE) staining or thymidine incorporation, we measure Teff proliferation and assess the inhibitory effects of Tregs.
  • Cytokine Secretion Analysis: We quantify cytokines such as IL-2, IFN-γ, and TGF-β in the culture supernatants using ELISA or multiplex assays to evaluate the immunomodulatory effects of Tregs.
  • Flow Cytometry: Analyzing surface and intracellular markers on Teff and Tregs, we assess activation status, differentiation, and suppression-related markers, providing detailed insights into the cellular interactions.
  • Functional Assays: We perform additional functional assays, including cytotoxicity assays and apoptosis assays, to comprehensively evaluate the suppressive effects of Tregs on Teff cells.
• Data Analysis and Reporting
  
  • Statistical Analysis: We employ advanced statistical methods to analyze experimental data, ensuring robustness and reproducibility of the results.
  • Graphical Representation: Our reports include detailed graphs and charts, illustrating key findings and enabling easy interpretation of the data.
  • Comprehensive Reports: Each project is concluded with a comprehensive report that includes methods, raw data, analyzed results, and interpretation, providing a complete overview of the findings.
• Customization
  
  • Tailored Services: We offer customized assay development and optimization based on specific client needs, ensuring that the experimental design aligns perfectly with research objectives.

By leveraging state-of-the-art technologies and a team of seasoned experts, Creative Biolabs guarantees precise, reproducible, and high-quality data to support your research endeavors. Our commitment to excellence ensures that your studies on Treg function and immunomodulation are conducted with the utmost accuracy and reliability.

Creative Biolabs, with its wealth of experience and cutting-edge technology, offers industry-leading in vitro Treg suppression assay services. We pride ourselves on delivering exceptional in vitro Treg suppression assay services tailored to meet your unique research requirements. Our expert team is dedicated to providing the most reliable data support for your research, ensuring every experimental result is precise and accurate. Reach out to us today to discover how we can contribute to your success in immunological studies and drug development.

Reference

1. McCallion, Oliver, et al. "Regulatory T-cell therapy approaches." Clinical and Experimental Immunology 211.2 (2023): 96-107.

For Research Use Only | Not For Clinical Use